Clinical Trial Results in Children
Novo Nordisk announced on September 7, 2026, that 40.4 per cent of children between 6 and 12 years old no longer met the clinical definition of obesity after 68 weeks of semaglutide treatment. The participants, all part of the company's STEP Young trial, received a once-weekly injection of the medication alongside a lifestyle modification plan. This regimen included a reduced-calorie diet and increased physical activity levels.
Martin Holst Lange, the chief scientific officer at Novo Nordisk, stated the company is encouraged by these findings. He noted that the medication offers a potential medical path for children struggling with obesity who have not found success through other means. The trial reached its primary goal by demonstrating a superior reduction in body mass index compared to the group that received a placebo. Researchers confirmed the safety and tolerability of the drug among this younger age group remained consistent with previous data observed in adult and adolescent cohorts.
Context of Rising Usage
While this trial provides new data, the use of GLP-1 weight-loss drugs in children remains a subject of intense debate among healthcare providers. A study published just days before this announcement revealed that prescriptions for these drugs in children under 12 have surged more than 300-fold since 2019. This growth occurred despite the fact that regulators have not formally approved these medications for this specific age range. Doctors and parents are navigating a environment where demand for treatment often outpaces established pediatric guidelines.
Implications for Future Medical Practice
What happens next depends on how regulatory bodies review the STEP Young trial data. The pharmaceutical industry is closely monitoring whether this evidence leads to an expansion of approved labels for semaglutide. Broadening usage to younger children presents a significant shift in how pediatric obesity is treated on a global scale. Public health experts continue to weigh the benefits of chemical intervention against the long-term unknowns of using such potent medications in growing bodies. Families and practitioners are left to reconcile these results with the realities of clinical practice and access.